FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 321:501-507 August 24, 1989 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death. The medications were randomly assigned to 3069 patients with recent transient or mild persistent focal cerebral or retinal ischemia. Follow-up lasted for two to six years. The three-year event rate for nonfatal stroke or death from any cause was 17 percent for ticlopidine and 19 percent for aspirin--a 12 percent risk reduction (95 percent confidence interval, -2 to 26 percent) with ticlopidine (P = 0.048 for cumulative Kaplan-Meier estimates). The rates of fatal and nonfatal stroke at three years were 10 percent for ticlopidine and 13 percent for aspirin--a 21 percent risk reduction (95 percent confidence interval, 4 to 38 percent) with ticlopidine (P = 0.024 for cumulative Kaplan-Meier estimates). Ticlopidine was more effective than aspirin in both sexes. The adverse effects of aspirin included diarrhea (10 percent), rash (5.5 percent), peptic ulceration (3 percent), gastritis (2 percent), and gastrointestinal bleeding (1 percent). With ticlopidine, diarrhea (20 percent), skin rash (14 percent), and severe but reversible neutropenia (less than 1 percent) were noted. The mean increase in total cholesterol level was 9 percent with ticlopidine and 2 percent with aspirin (P less than 0.01). The ratios of high-density lipoprotein and low-density lipoprotein to total cholesterol were similar in both treatment groups. We conclude that ticlopidine was somewhat more effective than aspirin in preventing strokes in this population, although the risks of side effects were greater.

Source Information

New York University Medical Center, Department of Neurology, NY 10016.

This article has been cited by other articles:

• Verstuyft, C., Simon, T., Kim, R. B. (2009). Personalized medicine and antiplatelet therapy: ready for prime time?. Eur Heart J 30: 1943-1963 [Full Text]  
• Adams, H. P. Jr (2009). Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc. 84: 43-51 [Abstract] [Full Text]  
• Talelli, P., Greenwood, R. J. (2008). Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. Ther Adv Cardiovasc Dis 2: 387-405 [Abstract]  
• Sacco, R. L., Diener, H.-C., Yusuf, S., Cotton, D., Ounpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., Bornstein, N., Chan, B. P.L., Chen, S.-T., Cunha, L., Dahlof, B., De Keyser, J., Donnan, G. A., Estol, C., Gorelick, P., Gu, V., Hermansson, K., Hilbrich, L., Kaste, M., Lu, C., Machnig, T., Pais, P., Roberts, R., Skvortsova, V., Teal, P., Toni, D., VanderMaelen, C., Voigt, T., Weber, M., Yoon, B.-W., the PRoFESS Study Group, (2008). Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. NEJM 359: 1238-1251 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., Teal, P. (2008). Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 630S-669S [Abstract] [Full Text]  
• Baumgartner, R. W. (2008). Network meta-analysis of antiplatelet treatments for secondary stroke prevention. Eur Heart J 29: 1082-1083 [Full Text]  
• Thijs, V., Lemmens, R., Fieuws, S. (2008). Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J 29: 1086-1092 [Abstract] [Full Text]  
• O'Donnell, M. J., Hankey, G. J., Eikelboom, J. W. (2008). Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review. Stroke 39: 1638-1646 [Abstract] [Full Text]  
• BAKHRU, M. R., BHATT, D. L. (2008). INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?. Cleveland Clinic Journal of Medicine 75: 289-295 [Abstract] [Full Text]  
• Comerota, A. J., Thakur, S. (2008). Antiplatelet Therapy for Vascular Interventions. PERSPECT VASC SURG ENDOVASC THER 20: 28-35 [Abstract]  
• Khella, S., Bleicher, M. B. (2007). Stroke and Its Prevention in Chronic Kidney Disease. CJASN 2: 1343-1351 [Abstract] [Full Text]  
• Dhamoon, M. S., Tai, W., Boden-Albala, B., Rundek, T., Paik, M. C., Sacco, R. L., Elkind, M. S.V. (2007). Risk of Myocardial Infarction or Vascular Death After First Ischemic Stroke: The Northern Manhattan Study. Stroke 38: 1752-1758 [Abstract] [Full Text]  
• Liao, J. K. (2007). Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer?. Circulation 115: 1615-1621 [Abstract] [Full Text]  
• American Society of Interventional & Therapeutic N, , Society for Cardiovascular Angiography and Interve, , Society for Vascular Medicine and Biology, , Society of Interventional Radiology, , Bates, E. R., Babb, J. D., Casey, D. E. Jr, Cates, C. U., Duckwiler, G. R., Feldman, T. E., Gray, W. A., Ouriel, K., Peterson, E. D., Rosenfield, K., Rundback, J. H., Safian, R. D., Sloan, M. A., White, C. J., Harrington, R. A., Abrams, J., Anderson, J. L., Bates, E. R., Eisenberg, M. J., Grines, C. L., Hlatky, M. A., Lichtenberg, R. C., Lindner, J. R., Pohost, G. M., Schofield, R. S., Shubrooks, S. J. JR, Stein, J. H., Tracy, C. M., Vogel, R. A., Wesley, D. J. (2007). ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting). J Am Coll Cardiol 49: 126-170 [Full Text]  
• Ibanez, B., Vilahur, G., Badimon, J. J. (2006). Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl 8: G3-G9 [Abstract] [Full Text]  
• Zaitsev, S., Danielyan, K., Murciano, J.-C., Ganguly, K., Krasik, T., Taylor, R. P., Pincus, S., Jones, S., Cines, D. B., Muzykantov, V. R. (2006). Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 108: 1895-1902 [Abstract] [Full Text]  
• Lu, W.-J., Huang, J.-d., Lai, M.-L. (2006). The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine.. J Clin Pharmacol 46: 628-634 [Abstract] [Full Text]  
• Dhamoon, M. S., Sciacca, R. R., Rundek, T., Sacco, R. L., Elkind, M.S.V. (2006). Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study. Neurology 66: 641-646 [Abstract] [Full Text]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e409-e449 [Abstract] [Full Text]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 577-617 [Abstract] [Full Text]  
• Vijungco, J., Eskandari, M. K. (2005). New Treatments for Cerebrovascular Disease. PERSPECT VASC SURG ENDOVASC THER 17: 279-287 [Abstract]  
• Touze, E., Varenne, O., Chatellier, G., Peyrard, S., Rothwell, P. M., Mas, J.-L. (2005). Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke 36: 2748-2755 [Abstract] [Full Text]  
• Gebel, J. M. Jr (2005). Secondary Stroke Prevention With Antiplatelet Therapy With Emphasis on the Cardiac Patient: A Neurologist's View. J Am Coll Cardiol 46: 752-755 [Abstract] [Full Text]  
• Paraskevas, K. I., Daskalopoulou, S. S., Daskalopoulos, M. E., Liapis, C. D. (2005). Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence?. ANGIOLOGY 56: 539-552 [Abstract]  
• Jamieson, D. G., Parekh, A., Ezekowitz, M. D. (2005). Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents. J CARDIOVASC PHARMACOL THER 10: 153-161 [Abstract]  
• Abciximab Emergent Stroke Treatment Trial Investi, (2005). Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial. Stroke 36: 880-890 [Abstract] [Full Text]  
• Boulanger, J.-M., Coutts, S. B., Hill, M. D., Demchuk, A. M., Buchan, A. M., For the Calgary Stroke Program, , Purroy, F., Montaner, J., Delgado, P., Alvarez-Sabin, J. (2005). Use of Magnetic Resonance Imaging in Predicting Further Vascular Events Among Patients With Transient Ischemic Attacks * Response:. Stroke 36: 526-528 [Full Text]  
• Tran, H., Anand, S. S. (2004). Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease. JAMA 292: 1867-1874 [Abstract] [Full Text]  
• Andersohn, F, Hagmann, F G, Garbe, E (2004). Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 90: e57-e57 [Abstract] [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., Teal, P. (2004). Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 483S-512S [Abstract] [Full Text]  
• Creager, M. A., Jones, D. W., Easton, J. D., Halperin, J. L., Hirsch, A. T., Matsumoto, A. H., O'Gara, P. T., Safian, R. D., Schwartz, G. L., Spittell, J. A. (2004). Atherosclerotic Vascular Disease Conference: Writing Group V: Medical Decision Making and Therapy. Circulation 109: 2634-2642 [Full Text]  
• Naka, H., Nomura, E., Wakabayashi, S., Kajikawa, H., Kohriyama, T., Mimori, Y., Nakamura, S., Matsumoto, M. (2004). Frequency of Asymptomatic Microbleeds on T2*-Weighted MR Images of Patients with Recurrent Stroke: Association with Combination of Stroke Subtypes and Leukoaraiosis. Am. J. Neuroradiol. 25: 714-719 [Abstract] [Full Text]  
• Sacco, R. L. (2004). Risk factors for TIA and TIA as a risk factor for stroke. Neurology 62: S7-S11 [Full Text]  
• Eliasziw, M., Kennedy, J., Hill, M. D., Buchan, A. M., Barnett, H. J.M. (2004). Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ 170: 1105-1109 [Abstract] [Full Text]  
• Broderick, J. P. (2004). William M. Feinberg Lecture: Stroke Therapy in the Year 2025: Burden, Breakthroughs, and Barriers to Progress. Stroke 35: 205-211 [Abstract] [Full Text]  
• Goldstein, L.B., Matchar, D.B., Hoff-Lindquist, J., Samsa, G.P., Horner, R.D. (2003). VA Stroke Study: Neurologist care is associated with increased testing but improved outcomes. Neurology 61: 792-796 [Abstract] [Full Text]  
• Adams, R. J., Chimowitz, M. I., Alpert, J. S., Awad, I. A., Cerqueria, M. D., Fayad, P., Taubert, K. A. (2003). Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 108: 1278-1290 [Full Text]  
• Adams, R. J., Chimowitz, M. I., Alpert, J. S., Awad, I. A., Cerqueria, M. D., Fayad, P., Taubert, K. A. (2003). Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 34: 2310-2322 [Full Text]  
• Gorelick, P. B., Richardson, D., Kelly, M., Ruland, S., Hung, E., Harris, Y., Kittner, S., Leurgans, S. (2003). Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients: A Randomized Trial. JAMA 289: 2947-2957 [Abstract] [Full Text]  
• Moore, W. S. (2003). Resolved: NASCET and ACAS Need Not Be Repeated: The Affirmative Position. Arch Neurol 60: 775-778 [Full Text]  
• Matias-Guiu, J., Ferro, J. M., Alvarez-Sabin, J., Torres, F., Jimenez, M. D., Lago, A., Melo, T., Tong, D. C. (2003). Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: The TACIP Study: A Randomized, Double-Blind, Multicenter Trial * Can Aspirin Ever Be Surpassed for Stroke Prevention?. Stroke 34: 840-848 [Abstract] [Full Text]  
• Skurnik, Y. D, Tcherniak, A., Edlan, K., Sthoeger, Z. (2003). Ticlopidine-Induced Cholestatic Hepatitis. The Annals of Pharmacotherapy 37: 371-375 [Abstract] [Full Text]  
• van Gestel, M. A., Heemskerk, J. W.M., Slaaf, D. W., Heijnen, V. V.T., Reneman, R. S., oude Egbrink, M. G.A. (2003). In Vivo Blockade of Platelet ADP Receptor P2Y12 Reduces Embolus and Thrombus Formation but Not Thrombus Stability. Arterioscler. Thromb. Vasc. Bio. 23: 518-523 [Abstract] [Full Text]  
• Tu, J. V., Gong, Y. (2003). Trends in Treatment and Outcomes for Acute Stroke Patients in Ontario, 1992-1998. Arch Intern Med 163: 293-297 [Abstract] [Full Text]  
• Diener, H.-C. (2002). Aspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke--Against. Stroke 33: 2138-2139 [Full Text]  
• Mouradian, M. S., Majumdar, S. R., Senthilselvan, A., Khan, K., Shuaib, A. (2002). How Well Are Hypertension, Hyperlipidemia, Diabetes, and Smoking Managed After a Stroke or Transient Ischemic Attack?. Stroke 33: 1656-1659 [Abstract] [Full Text]  
• Izaguirre-Avila, R., Penia-Diaz, A. D. l., Barinagarrementeria-Aldatz, F., Gonzailez-Pacheco, H., Ramirez-Gutierrez, A. E., Ruiz-Sandoval, J. L., Quiroz-Martinez, A., Cantu-Brito, C. (2002). Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects with Cerebral or Coronary Atherosclerotic Disease. CLIN APPL THROMB HEMOST 8: 169-177 [Abstract]  
• Ertorer, M. E., Gokcel, A., Savas, L., Kocak, R. (2002). Ticlopidine-Induced Marrow Aplasia Treated with Cyclosporine. CLIN APPL THROMB HEMOST 8: 183-185 [Abstract]  
• Dakik, H. A, Salti, I., Haidar, R., Uthman, I. W (2002). Drug points: Ticlopidine associated with acute arthritis. BMJ 324: 27-27 [Full Text]  
• Mohr, J.P., Thompson, J.L.P., Lazar, R.M., Levin, B., Sacco, R.L., Furie, K.L., Kistler, J.P., Albers, G.W., Pettigrew, L.C., Adams, H.P. Jr., Jackson, C.M., Pullicino, P., the Warfarin-Aspirin Recurrent Stroke Study Group, (2001). A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. NEJM 345: 1444-1451 [Abstract] [Full Text]  
• CAPLAN, L R (2001). Evidence based medicine: concerns of a clinical neurologist. J. Neurol. Neurosurg. Psychiatry 71: 569-574 [Full Text]  
• Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P., Camm, A.J., Cappato, R., Cobbe, S.M., Di Mario, C., Maron, B.J., McKenna, W.J., Pedersen, A.K., Ravens, U., Schwartz, P.J., Trusz-Gluza, M., Vardas, P., Wellens, H.J.J., Zipes, D.P. (2001). Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22: 1374-1450  
• Schuhlen, H., Kastrati, A., Pache, J.u., Dirschinger, J., Schomig, A. (2001). Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 37: 2066-2073 [Abstract] [Full Text]  
• Smith, S. C. Jr, Dove, J. T., Jacobs, A. K., Ward Kennedy, J., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., Gibbons, R. J., Alpert, J. P., Eagle, K. A., Faxon, D. P., Fuster, V., Gardner, T. J., Gregoratos, G., Russell, R. O., Smith, S. C. Jr (2001). ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 37: 2239-2239 [Full Text]  
• Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G. (2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest 119 : 39S-63S [Full Text]  
• Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W. (2001). Antithrombotic Agents in Coronary Artery Disease. Chest 119 : 228S-252S [Full Text]  
• Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., Teal, P. (2001). Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest 119 : 300S-320S [Full Text]  
• Popma, J. J., Ohman, E. M., Weitz, J., Lincoff, A. M., Harrington, R. A., Berger, P. (2001). Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. Chest 119 : 321S-336S [Full Text]  
• Monagle, P., Michelson, A. D., Bovill, E., Andrew, M. (2001). Antithrombotic Therapy in Children. Chest 119 : 344S-370S [Full Text]  
• (2000). The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21: 2033-2041 [Abstract]  
• Paradiso-Hardy, F. L., Angelo, C. M., Lanctot, K. L., Cohen, E. A. (2000). Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ 163: 1441-1448 [Abstract] [Full Text]  
• Thijs, V. N., Albers, G. W. (2000). Symptomatic intracranial atherosclerosis: Outcome of patients who fail antithrombotic therapy. Neurology 55: 490-498 [Abstract] [Full Text]  
• Holroyd-Leduc, J. M., Kapral, M. K., Austin, P. C., Tu, J. V. (2000). Sex Differences and Similarities in the Management and Outcome of Stroke Patients. Stroke 31: 1833-1837 [Abstract] [Full Text]  
• Liu, Z. C., Uetrecht, J. P. (2000). Metabolism of Ticlopidine by Activated Neutrophils: Implications for Ticlopidine-Induced Agranulocytosis. Drug Metab. Dispos. 28: 726-730 [Abstract] [Full Text]  
• Sari, R., Sevinc, A., Buyukberber, S. (2000). Ticlopidine-Induced Severe Agranulocytosis After the Placement of Coronary Artery Stent: A Case Report. ANGIOLOGY 51: 591-593 [Abstract]  
• Cohen, S. N., Easton, J. D., Wilterdink, J. L. (2000). Dipyridamole Plus Aspirin in Cerebrovascular Disease. Arch Neurol 57: 1086-1087 [Full Text]  
• Hankey, G. J., Sudlow, C. L. M., Dunbabin, D. W. (2000). Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in Patients at High Risk of Vascular Disease? : A Systematic Review of the Evidence From Randomized Trials. Stroke 31: 1779-1784 [Abstract] [Full Text]  
• Sacco, R. L., Elkind, M. S. (2000). Update on Antiplatelet Therapy for Stroke Prevention. Arch Intern Med 160: 1579-1582 [Full Text]  
• Verstraete, M., Prentice, C. R. M., Samama, M., Verhaeghe, R. (2000). A European View on the North American Fifth Consensus on Antithrombotic Therapy. Chest 117: 1755-1770 [Abstract] [Full Text]  
• Holloway, R. G., Benesch, C., Rush, S. R. (2000). Stroke prevention: Narrowing the evidence-practice gap. Neurology 54: 1899-1906 [Abstract] [Full Text]  
• Moy, B., Wang, J. C., Raffel, G. D., Marcoux II, J. P. (2000). Hemolytic Uremic Syndrome Associated With Clopidogrel: A Case Report. Arch Intern Med 160: 1370-1372 [Abstract] [Full Text]  
• O'Brien, M., Parness, I. A., Neufeld, E. J., Baker, A. L., Sundel, R. P., Newburger, J. W. (2000). Ticlopidine Plus Aspirin for Coronary Thrombosis in Kawasaki Disease. Pediatrics 105: 64e-64 [Abstract] [Full Text]  
• Albers, G. W. (2000). Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients?. Neurology 54: 1022-1028 [Abstract] [Full Text]  
• Awtry, E. H., Loscalzo, J. (2000). Aspirin. Circulation 101: 1206-1218 [Full Text]  
• Connors III, J. J., Seidenwurm, D., Wojak, J. C., Hurst, R. W., Jensen, M. E., Wallace, R., Tomsick, T., Barr, J., Kerber, C., Russell, E., Nesbit, G. M., Fox, A. J., Tsai, F. Y. (2000). Treatment of Atherosclerotic Disease at the Cervical Carotid Bifurcation: Current Status and Review of the Literature. Am. J. Neuroradiol. 21: 444-450 [Full Text]  
• Brodison, A., Katira, R., More, R. S, Chauhan, A. (2000). Current practice: Antiplatelet use in interventional cardiology. Postgrad. Med. J. 76: 70-79 [Abstract] [Full Text]  
• Klein, L. W., Calvin, J. E. (1999). Use of clopidrogel in coronary stenting: what was the question?. J Am Coll Cardiol 34: 1895-1898 [Full Text]  
• Bennett, C. L., Davidson, C. J., Raisch, D. W., Weinberg, P. D., Bennett, R. H., Feldman, M. D. (1999). Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine in the Setting of Coronary Artery Stents and Stroke Prevention. Arch Intern Med 159: 2524-2528 [Abstract] [Full Text]  
• Albers, G. W., Hart, R. G., Lutsep, H. L., Newell, D. W., Sacco, R. L. (1999). Supplement to the Guidelines for the Management of Transient Ischemic Attacks : A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30: 2502-2511 [Full Text]  
• Quinn, M. J., Fitzgerald, D. J. (1999). Ticlopidine and Clopidogrel. Circulation 100: 1667-1672 [Abstract] [Full Text]  
• Altman, R., Scazziota, A., Rouvier, J., Gonzalez, C. (1999). Effects of Ticlopidine or Ticlopidine Plus Aspirin on Platelet Aggregation and ATP Release in Normal Volunteers: Why Aspirin Improves Ticlopidine Antiplatelet Activity. CLIN APPL THROMB HEMOST 5: 243-246 [Abstract]  
• Bartzokis, G., Goldstein, I. B., Hance, D. B., Beckson, M., Shapiro, D., Lu, P. H., Edwards, N., Mintz, J., Bridge, P. (1999). The Incidence of T2-Weighted MR Imaging Signal Abnormalities in the Brain of Cocaine-Dependent Patients Is Age-Related and Region-Specific. Am. J. Neuroradiol. 20: 1628-1635 [Abstract] [Full Text]  
• (1999). {blacktriangledown}Clopidogrel and {blacktriangledown}ticlopidine - improvements on aspirin?. DTB 37: 59-61 [Abstract] [Full Text]  
• Davis, M., Barer, D. (1999). Neuroprotection in acute ischaemic stroke. II: Clinical potential. Vasc Med 4: 149-163 [Abstract]  
• Gorelick, P. B., Born, G. V. R., D'Agostino, R. B., Hanley, D. F. Jr, Moye, L., Pepine, C. J. (1999). Therapeutic Benefit : Aspirin Revisited in Light of the Introduction of Clopidogrel. Stroke 30: 1716-1721 [Abstract] [Full Text]  
• Holloway, R. G., Benesch, C. G., Rahilly, C. R., Courtright, C. E. (1999). A Systematic Review of Cost-Effectiveness Research of Stroke Evaluation and Treatment. Stroke 30: 1340-1349 [Abstract] [Full Text]  
• ALGRA, A, VAN GIJN, J, ALGRA, A, KOUDSTAAL, P J (1999). Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?. J. Neurol. Neurosurg. Psychiatry 66: 557-559 [Full Text]  
• Salachas, A. J., Patsilinakos, S. P., Tsilias, K. P., Stefanou, I., Margaris, N. G., Ifantis, G. P., Kranidis, A. J., Tavernarakis, A. G., Rokas, S. G., Antonellis, I. (1999). Elective Intracoronary Micro-Stent IITM Implantation Without Quantitative Coronary Angiography or Intravascular Ultrasound Guidance and Without Subsequent Anticoagulation: Short- and Long-Term Results. ANGIOLOGY 50: 381-391 [Abstract]  
• Bednar, M. M., Gross, C. E. (1999). Antiplatelet Therapy in Acute Cerebral Ischemia. Stroke 30: 887-893 [Abstract] [Full Text]  
• Chen, D. K., Kim, J. S., Sutton, D. M. C. (1999). Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use: A Report of 3 Cases and Review of the Literature. Arch Intern Med 159: 311-314 [Abstract] [Full Text]  
• Berger, P. B., Bell, M. R., Hasdai, D., Grill, D. E., Melby, S., Holmes, D. R. Jr (1999). Safety and Efficacy of Ticlopidine for Only 2 Weeks After Successful Intracoronary Stent Placement. Circulation 99: 248-253 [Abstract] [Full Text]  
• He, J., Whelton, P. K., Vu, B., Klag, M. J. (1998). Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials. JAMA 280: 1930-1935 [Abstract] [Full Text]